Literature DB >> 20562013

Intradermal administration of RiVax protects mice from mucosal and systemic ricin intoxication.

Praveena S Marconescu1, Joan E Smallshaw, Laurentiu M Pop, Stephen L Ruback, Ellen S Vitetta.   

Abstract

Ricin toxin is a CDC level B biothreat. We have developed a ricin vaccine, RiVax, which is a recombinant mutant of ricin A chain. RiVax is safe, immunogenic and protective in mice when administered intramuscularly (IM). We have now attempted to increase the utility and immunogenicity of RiVax by administering it intradermally (ID) with or without alum. Without alum, Rivax administered by the ID and IM routes was equally immunogenic and protective. With alum, ID vaccinations were more immunogenic and protective against both systemic and mucosal challenge with ricin and superior in protecting animals from ricin-induced lung damage. (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20562013      PMCID： PMC2908217          DOI： 10.1016/j.vaccine.2010.05.045

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  33 in total

1.  Structure-based design and characterization of novel platforms for ricin and shiga toxin inhibition.

Authors:  Darcie J Miller; Kabyadi Ravikumar; Huafeng Shen; Jung-Keun Suh; Sean M Kerwin; Jon D Robertus
Journal:  J Med Chem       Date:  2002-01-03       Impact factor: 7.446

2.  Finding a new vaccine in the ricin protein fold.

Authors:  Mark A Olson; John H Carra; Virginia Roxas-Duncan; Robert W Wannemacher; Leonard A Smith; Charles B Millard
Journal:  Protein Eng Des Sel       Date:  2004-06-08       Impact factor: 1.650

3.  Intradermal, subcutaneous or intramuscular administration of hepatitis B vaccine: side effects and antibody response.

Authors:  M Wahl; S Hermodsson
Journal:  Scand J Infect Dis       Date:  1987

4.  The use of anti-ricin antibodies to protect mice intoxicated with ricin.

Authors:  B M Foxwell; S I Detre; T A Donovan; P E Thorpe
Journal:  Toxicology       Date:  1985-01       Impact factor: 4.221

Review 5.  New strategies for using mucosal vaccination to achieve more effective immunization.

Authors:  R I Walker
Journal:  Vaccine       Date:  1994-04       Impact factor: 3.641

6.  Mice are actively immunized after passive monoclonal antibody prophylaxis and ricin toxin challenge.

Authors:  P V Lemley; D C Wright
Journal:  Immunology       Date:  1992-07       Impact factor: 7.397

7.  A phase I evaluation of inactivated influenza A/H5N1 vaccine administered by the intradermal or the intramuscular route.

Authors:  Shital M Patel; Robert L Atmar; Hana M El Sahly; Thomas R Cate; Wendy A Keitel
Journal:  Vaccine       Date:  2009-11-18       Impact factor: 3.641

Review 8.  Aluminum salts in vaccines--US perspective.

Authors:  Norman W Baylor; William Egan; Paul Richman
Journal:  Vaccine       Date:  2002-05-31       Impact factor: 3.641

9.  A novel recombinant vaccine which protects mice against ricin intoxication.

Authors:  Joan E Smallshaw; Ana Firan; John R Fulmer; Stephen L Ruback; Victor Ghetie; Ellen S Vitetta
Journal:  Vaccine       Date:  2002-09-10       Impact factor: 3.641

Review 10.  Ricin: structure, mode of action, and some current applications.

Authors:  J M Lord; L M Roberts; J D Robertus
Journal:  FASEB J       Date:  1994-02       Impact factor: 5.191
View more
  18 in total

1.  Recent advances in the development of vaccines against ricin.

Authors:  Robert N Brey; Nicholas J Mantis; Seth H Pincus; Ellen S Vitetta; Leonard A Smith; Chad J Roy
Journal:  Hum Vaccin Immunother       Date:  2016-01-25       Impact factor: 3.452

2.  Pilot phase IB clinical trial of an alhydrogel-adsorbed recombinant ricin vaccine.

Authors:  Ellen S Vitetta; Joan E Smallshaw; John Schindler
Journal:  Clin Vaccine Immunol       Date:  2012-08-22

3.  Comparative efficacy of two leading candidate ricin toxin a subunit vaccines in mice.

Authors:  Joanne M O'Hara; Robert N Brey; Nicholas J Mantis
Journal:  Clin Vaccine Immunol       Date:  2013-03-20

Review 4.  Immunity to ricin: fundamental insights into toxin-antibody interactions.

Authors:  Joanne M O'Hara; Anastasiya Yermakova; Nicholas J Mantis
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

5.  Novel Ricin Subunit Antigens With Enhanced Capacity to Elicit Toxin-Neutralizing Antibody Responses in Mice.

Authors:  Newton Wahome; Erin Sully; Christopher Singer; Justin C Thomas; Lei Hu; Sangeeta B Joshi; David B Volkin; Jianwen Fang; John Karanicolas; Donald J Jacobs; Nicholas J Mantis; C Russell Middaugh
Journal:  J Pharm Sci       Date:  2016-03-15       Impact factor: 3.534

6.  Vaccine-induced intestinal immunity to ricin toxin in the absence of secretory IgA.

Authors:  Lori M Neal; Elizabeth A McCarthy; Carolyn R Morris; Nicholas J Mantis
Journal:  Vaccine       Date:  2010-11-27       Impact factor: 3.641

Review 7.  Progress and challenges associated with the development of ricin toxin subunit vaccines.

Authors:  David J Vance; Nicholas J Mantis
Journal:  Expert Rev Vaccines       Date:  2016-04-06       Impact factor: 5.217

8.  Enhancement of humoral immunity by the type II heat-labile enterotoxin LT-IIb is dependent upon IL-6 and neutrophils.

Authors:  Christopher J Greene; John C Hu; David J Vance; Yinghui Rong; Lorrie Mandell; Natalie King-Lyons; Patricia Masso-Welch; Nicholas J Mantis; Terry D Connell
Journal:  J Leukoc Biol       Date:  2016-04-08       Impact factor: 4.962

9.  The need for continued development of ricin countermeasures.

Authors:  Ronald B Reisler; Leonard A Smith
Journal:  Adv Prev Med       Date:  2012-03-26

10.  Structure of RiVax: a recombinant ricin vaccine.

Authors:  Patricia M Legler; Robert N Brey; Joan E Smallshaw; Ellen S Vitetta; Charles B Millard
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2011-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.